Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Medically reviewed by Archana Sharma, DO HER2-positive (HER2+) breast cancer has more human epidermal growth factor receptor ...

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...

OS Therapies, Inc., a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, announced that it received a Notice of Allowance from the United ...

A new study on circulating tumor DNA (ctDNA) testing for advanced breast cancer has unveiled encouraging results, with high ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

New, less damaging treatments are giving some patients the choice to try to preserve their ability to have children after ...

San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.See Healio’s highlights in H ...

Based on data from the Beamion LUNG-1 trial, the FDA granted a priority review to zongertinib for patients with HER2-mutant ...

For years, breast cancer treatment has been guided by genetic alterations found in tumor tissue, typically through invasive biopsies.

The treatment landscape for HER2-positive NSCLC is rapidly evolving as research continues to reveal the genetic drivers of these tumors. Emerging therapies like Pyrotinib (Jiangsu HengRui Medicine), ...